VivoSeq
Oncology

Renal Cell Carcinoma

322

Pipeline Programs↗

124

Active Trials↗

98

Companies Involved↗

Renal Cell Carcinoma is a highly competitive landscape with 322 programs across 98 companies. The most active players are Celldex Therapeutics, Grit Biotechnology, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 19 therapies are approved with 43 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

89/100

Pipeline Velocity

55/100

Mech. Concentration

5/100

Completion Rate

71/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Celldex Therapeutics

2 programs

Phase 1G

Grit Biotechnology

2 programs

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

2 programs

Phase 1M

Mirati Therapeutics Inc.

1 program

Phase 1A

Allogene Therapeutics

1 program

Phase 1J

Jian Lin

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical19

Nivolumab

Bristol-Myers Squibb

Ketorolac Tromethamine

Roche

Bevacizumab

Bio-Thera Solutions

Ipilimumab

Bristol-Myers Squibb

Propofol

Fresenius Kabi Oncology Ltd.

Phase 153

Hydroxychloroquine

Alnylam Pharmaceuticals

Cemiplimab

Regeneron

Siltuximab

RECORDATI GROUP

Gefitinib

AstraZeneca

Sitravatinib

Mirati Therapeutics Inc.

Phase 2188

Pembrolizumab

Merck & Co.

Talazoparib

Pfizer

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Entinostat

Syndax Pharmaceuticals

Fluzoparib

Risen (Suzhou) Pharma Tech Co., Ltd.

Phase 343

Tremelimumab

AstraZeneca

Epacadostat

Incyte

Toripalimab

Coherus Oncology, Inc.

Belzutifan

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Dovitinib

Novartis

Approved19

Regorafenib

Bayer

Indocyanine Green

CHX Technologies Inc.

Celecoxib

Philadelphia Eye Associates

Mycophenolate Mofetil

Roche

Testosterone Undecanoate

Grupo Espanol de Tumores Neuroendocrinos

Analysis

Modality Breakdown

76%

Small molecule

239 of 315 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody4514%Protein / enzyme113%Cell therapy103%Vaccine62%Peptide2<1%Radiopharmaceutical2<1%

Small molecule leads; the ring shows all 315 classified programs, each share of the total. Modality classified for 99% of 364 pipeline programs.

Analysis

Trial Status

494

clinical trials

Completed229 · 46%
Terminated77 · 16%
Recruiting56 · 11%
Active, not recruiting49 · 10%
Unknown status44 · 9%
Not yet recruiting19 · 4%
Other20 · 4%

Clinical Trials

Trial Activity

494 trials

Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT07301827·66 enrolled
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Recruiting·YYonsei University·Phase 2·NCT07469683·78 enrolled
A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Recruiting·RRenJi Hospital·Phase 2·NCT06035224·28 enrolled
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Recruiting·JJinling Hospital, China·Phase 2·NCT06255223·35 enrolled
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT05931393·18 enrolled
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05048212·20 enrolled
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Recruiting·—·Phase 1·NCT05733715·30 enrolled
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
Recruiting·JJemincare·Phase 1·NCT06321250·80 enrolled
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06053658·48 enrolled
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Recruiting·—·Phase 2·NCT07123090·25 enrolled
Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma
Recruiting·—·N/A·NCT04053855·100 enrolled
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
Recruiting·UUniversity of Oklahoma·Phase 2·NCT07223541·72 enrolled
Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
Recruiting·—·Phase 2·NCT06794229·69 enrolled
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT07195682·125 enrolled
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05969496·17 enrolled
Page 1 of 33

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)